Plasma neutrophil gelatinase-associated lipocalin as a potential predictor of adverse renal outcomes in immunoglobulin A nephropathy

Ga-Young Park, Chung-Hoon Yu, Jun-Seop Kim, Yun-Jeong Kang, Owen Kwon, Ji-Young Choi, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, and Sun-Hee Park

Department of Internal Medicine, Kyungpook National University School of Medicine and Clinical Research Center for End Stage Renal Disease, Daegu, Korea

**Background/Aims:** Neutrophil gelatinase-associated lipocalin (NGAL) is a well-known biomarker of acute kidney injury. We evaluated the value of plasma NGAL (pNGAL) as an independent predictor of prognosis in immunoglobulin A nephropathy (IgAN).

**Methods:** In total, 91 patients with biopsy-proven IgAN at a single center were evaluated. pNGAL was measured using a commercial enzyme-linked immunosorbent assay kit (R&D Systems). Adverse renal outcome was defined as chronic kidney disease (CKD) stage 3 or above at the last follow-up. Pearson correlation coefficient and Cox regression were used for analyses.

**Results:** The mean age of all patients (male:female, 48:43) was 35 years (range, 18 to 77). pNGAL ranged between 21.68 and 446.40 ng/mL (median, 123.97) and showed a correlation with age ($r = 0.332$, $p = 0.001$), creatinine ($r = 0.336$, $p = 0.001$), estimated glomerular filtration rate ($r = -0.397$, $p < 0.001$), uric acid ($r = 0.289$, $p = 0.006$), and the protein-to-creatinine ratio ($r = 0.288$, $p = 0.006$). During a mean follow-up period of 37.6 months, 11 patients (12.1%) had CKD stage 3 or above. In a multivariate Cox regression model, hypertension (hazard ratio [HR], 8.779; 95% confidence interval [CI], 1.526 to 50.496; $p = 0.015$), proteinuria > 1 g/day (HR, 5.184; 95% CI, 1.124 to 23.921; $p = 0.035$), and pNGAL (HR, 1.012; 95% CI, 1.003 to 1.022; $p = 0.013$) were independent predictors associated with adverse renal outcome.

**Conclusions:** pNGAL showed strong correlations with other clinical prognostic factors and was also an independent predictor of adverse renal outcome. We suggest pNGAL as a potential predictor for prognosis in IgAN, while further studies are needed to confirm the clinical value.

**Keywords:** Glomerulonephritis, IGA; Neutrophil gelatinase-associated lipocalin; Prognosis; Renal insufficiency, chronic

**INTRODUCTION**

Immunoglobulin A nephropathy (IgAN) is the most common cause of primary glomerulonephritis worldwide and a frequent cause of end-stage renal disease (ESRD) in patients with primary glomerular disease [1]. Glomeruli typically contain generalized diffuse granular mesangial deposits of IgA. IgAN is generally regarded as an immune complex-mediated glomerulonephritis. The characteristic presentation is gross hematuria at the...
time of an infectious episode. Patients with IgAN have a variable clinical course, from a benign condition to progressive deterioration in kidney function over time. However, in many patients, disease progression is slow, with 14% to 39% of patients developing ESRD over a 20-year period after diagnosis [2]. Previous studies have identified several potential clinical predictors for progression, including degree of renal impairment at diagnosis, proteinuria, albumin level, high blood pressure at presentation, age, and male gender [3-5]. Several histological features have also been shown to be associated with a progressive course. However, prediction of renal outcome in an individual patient remains difficult. For decisions regarding the course of treatment, more accurate prognostic predictors are needed.

Several recent studies on early predictive biomarkers of both acute kidney injury (AKI) and chronic kidney disease (CKD) have been reported [6]. Among them, neutrophil gelatinase-associated lipocalin (NGAL) is one of the most promising novel biomarkers. NGAL is a small (25 kDa) protein belonging to the lipocalin family, which is released from kidney tubular cells after harmful stimuli [7]. After renal injury, NGAL is increased significantly in human kidney cortical tubules, blood, and urine [8]. NGAL has been identified as an early predictive biomarker for AKI [9]. However, recent studies have also suggested a possible role for NGAL in CKD [10,11]. In CKD, the rate of deterioration in renal function and adverse renal outcomes are associated with the degree of renal tubulointerstitial impairment rather than with the severity of glomerular lesions [12]. Involvement of several tubular proteins in the pathogenesis of tubular damage has been reported [13]. NGAL has been shown to represent a biomarker for degree of tubulointerstitial damage in patients with CKD [14,15].

We hypothesized that NGAL could be used as a new prognostic predictor with its potential role in tubular injury in IgAN. Thus, we attempted to determine whether plasma NGAL (pNGAL) was associated with other clinical prognostic factors and a potential biomarker for predicting outcomes in patients with IgAN.

**METHODS**

**Subjects**
Among 406 patients diagnosed with biopsy-proven IgAN in the Department of Internal Medicine, Kyungpook National University, from February 2002 to August 2010, we examined 91 patients with available samples for analysis and clinical data. The study was approved by the local Ethics Committee (IRB No. 2013-04-039). All patients gave written informed consent.

Patients with cancer, infection, or autoimmune disease were excluded to avoid potential confounding factors. The medical records were reviewed retrospectively and clinical data, including age, gender, presence of hypertension (HTN), histological findings, and treatment methods at the time of renal biopsy, were recorded. Tubulointerstitial change was classified as absent (0%), mild (1% to 25%), moderate (26% to 50%), or severe (>50%). Mild or above was defined as tubular atrophy/interstitial fibrosis. The histological assessment of renal biopsies was performed according to the Haas classification. Haas subclass III or above was defined as higher histological grade. CKD stage 3 or above was defined as an adverse renal outcome.

**Laboratory measurements**
Common biochemical parameters, including urea, creatinine, uric acid, serum lipids, electrolytes, albumin, hemoglobin, and proteinuria, were measured at baseline in all patients, according to standard methods in the routine clinical laboratory. Additional blood samples were stored at –80°C until assayed.

At the time of renal biopsy, pNGAL was measured in all patients using a commercially available enzyme-linked immunosorbent assay test kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. Microplate wells were coated with a monoclonal antibody specific for NGAL. Standards and samples were pipetted into wells and any NGAL present was bound by the immobilized antibody. After incubation, the unbound conjugate was washed off and substrate solution was added to each well. The intensity of color developed was proportional to the concentration of NGAL in the patient plasma sample. pNGAL levels were expressed in nanograms per milliliter and the minimum detectable level was 0.012 ng/mL.
Statistical analysis
Data are reported as means ± standard deviation, median and interquartile range, or percentage frequency, as appropriate, and $t$ tests or one-way analysis of variance was used for comparisons among groups. Correlations between pNGAL and age, initial creatinine, estimated glomerular filtration rate (eGFR), uric acid, urinary protein-to-creatinine ratio (PCR), eGFR slope, and creatinine slope were assessed using Pearson correlation coefficients. eGFR is estimated GFR, calculated by the abbreviated Modification of Diet in Renal Disease equation: 186 × (creatinine / 88.4)$^{1.154}$ × age$^{-0.203}$ (× 0.742 if female).

The predictive value for renal outcome was analyzed by receiver operating characteristic (ROC) curve analysis, and the area under the curve (AUC) the ROC curve was calculated. Univariate and multivariate Cox regression analysis were performed for analysis of the association between clinical parameters and renal outcome. Statistical analyses were performed using the SPSS version 19.0 (IBM Co., Armonk, NY, USA). Results were considered significant if $p < 0.05$.

RESULTS

Baseline demographics
In total, 91 patients were included in the analyses. Baseline demographics are shown in Table 1. The mean age of the patients was 35 years (range, 18 to 77) at baseline. Of them, 48 patients (52.7%) were male. Of the patients, 22 (24.2%) had HTN, 17 (18.7%) reported a history of gross hematuria, and four (4.4%) had nephrotic-range proteinuria. Renal biopsies showed tubular atrophy/interstitial fibrosis in 30 patients (33.0%); six patients (6.6%) showed a higher histological grade. No patient was Haas subclass IV or above. Mean creatinine was 0.84 ± 0.23 mg/dL, with a mean eGFR of 104 ± 30 mL/min/1.73 m$^2$. Mean urinary PCR was 0.88 ± 1.21 mg/g. Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) were used in 62 patients (68.1%) and lipid-lowering agents in seven (7.7%).

Relationship between pNGAL and clinical variables
The mean concentration of pNGAL was 123.97 ± 74.50 ng/mL. On univariate baseline statistical correlation

| Characteristic | Value |
|---------------|-------|
| Age, yr       | 35 ± 13 (18–77) |
| Gender, male:female | 48:43 (52.7:47.3) |
| Hypertension  | 22 (24.2) |
| Gross hematuria | 17 (18.7) |
| Nephrotic syndrome | 4 (4.4) |
| Tubular atrophy/interstitial fibrosis | 30 (33.0) |
| Mild          | 23 (25.3) |
| Moderate      | 5 (5.5) |
| Severe        | 2 (2.2) |
| Haas classification | |
| Subclass I    | 31 (34.1) |
| Subclass II   | 54 (59.3) |
| Subclass III  | 6 (6.6) |
| Subclass IV, V | 0 |
| Plasma NGAL, ng/mL | 123.97 ± 74.50 (21.68–446.40) |
| Uric acid, mg/dL | 5.5 ± 1.7 (2.8–11.4) |
| Ca × P        | 33.3 ± 5.7 (23.4–45.1) |
| PCR, mg/g     | 0.88 ± 1.21 (0.03–6.67) |
| Follow-up     | |
| Length of follow-up, mon | 37.6 ± 19.9 (1.2–83.6) |
| Creatinine, mg/dL | 1.02 ± 0.58 (0.54–5.43) |
| eGFR, mL/min/1.73 m$^2$ | 93 ± 28 (53–145) |
| PCR, mg/g     | 0.52 ± 0.56 (0–3.10) |
| CKD stage 3 and above | 11 (12.1) |
| Treatment     | |
| ACEi or ARBs  | 62 (68.1) |
| Anti-lipidemic drug | 7 (7.7) |

Values are presented as mean ± SD (interquartile range) or number (%).

NGAL, neutrophil gelatinase-associated lipocalin; PCR, protein-creatinine ratio; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Figure 1. Linear regression analysis of (A) age, (B) creatinine, (C) estimated glomerular filtration rate (eGFR), (D) uric acid, (E) protein-creatinine ratio (PCR), (F) eGFR slope, (G) creatinine slope, and (H) total cholesterol. pNGAL, plasma neutrophil gelatinase-associated lipocalin.
cholesterol ($r = 0.167$, $p = 0.115$), eGFR slope ($r = 0.032$, $p = 0.760$), and creatinine slope ($r = 0.186$, $p = 0.077$) showed no correlation with pNGAL. In Table 2, clinical variables are shown according to pNGAL tertiles. Patients in the first tertile (i.e., those with relatively high pNGAL) had higher creatinine ($p < 0.001$), higher PCR ($p = 0.015$), lower eGFR ($p < 0.001$), and lower albumin ($p = 0.017$) versus those in other tertiles. In a chi-square analysis, patients were divided into low and high pNGAL groups using the median value. The high pNGAL group showed a significant association with tubular atrophy/interstitial fibrosis as a pathological feature ($p = 0.022$), HTN ($p = 0.004$), and nephrotic-range proteinuria ($p = 0.002$).

**Predictors of adverse renal outcome**

Mean follow-up duration was 37.6 ± 19.9 months. At the last follow-up, mean creatinine was 1.02 ± 0.58 mg/dL, with a mean eGFR of 91 ± 28 mL/min/1.73 m². Mean PCR was 0.54 ± 0.56 mg/g. We performed a Cox regression analysis to determine predictors of adverse renal outcome. In a univariate analysis, patients with CKD 3 or above were more likely to have concomitant HTN (hazard ratio [HR], 10.801; 95% confidence interval [CI], 2.264 to 51.536; $p = 0.003$), presence of tubular atrophy/interstitial fibrosis, and nephrotic-range proteinuria.

**Table 2. Comparison of baseline demographic, clinical, and biochemical data according to the concentration of baseline plasma neutrophil gelatinase-associated lipocalin**

| Characteristic                  | Plasma NGAL, ng/mL | $p$ value |
|--------------------------------|--------------------|-----------|
|                                | Lower (n = 30)     | Middle (n = 31) | Upper (n = 30) |
| Age, yr                        | (61.20 ± 19.28)    | (105.36 ± 11.53) | (205.96 ± 72.92) |
| Follow-up duration, mon        | 33 ± 12            | 33 ± 13      | 39 ± 14        | 0.081 |
| Baseline creatinine, mg/dL     | 0.72 ± 0.15        | 0.86 ± 0.17  | 0.96 ± 0.28    | <0.001|
| Baseline PCR, mg/g             | 0.53 ± 0.70        | 0.73 ± 1.04  | 1.38 ± 1.58    | 0.015 |
| Baseline uric acid, mg/dL      | 4.98 ± 1.32        | 5.55 ± 1.86  | 6.02 ± 1.77    | 0.059 |
| Baseline total cholesterol, mg/dL | 173 ± 47       | 170 ± 42    | 195 ± 56      | 0.101 |
| Baseline LDL, mg/dL            | 108 ± 43           | 109 ± 28    | 124 ± 46      | 0.273 |
| Baseline albumin, g/dL         | 4.38 ± 0.40        | 4.55 ± 0.49  | 4.19 ± 0.56   | 0.017 |

Values are presented as mean ± SD.

NGAL, neutrophil gelatinase-associated lipocalin; PCR, protein-creatinine ratio; LDL, low density lipoprotein.

**Table 3. Univariate Cox regression analysis of factors affecting adverse renal outcomes**

| Characteristic                  | $p$ value | HR     | 95% CI       |
|--------------------------------|-----------|--------|--------------|
| Male                           | 0.563     | 1.439  | 0.419–4.948  |
| Age                            | 0.052     | 1.045  | 1.000–1.093  |
| Hypertension                   | 0.003     | 10.801 | 2.264–51.536 |
| ACEi or ARBs                   | 0.576     | 1.816  | 0.225–14.662 |
| Gross hematuria                | 0.396     | 0.035  | 0–80.412     |
| Haas subclass III or above     | 0.526     | 0.043  | 0–722.358    |
| Nephrotic range proteinuria (≥ 3.5 g/day) | 0.247  | 3.501  | 0.419–29.218 |
| Document proteinuria (≥ 1 g/day) | 0.003  | 7.128  | 1.937–26.232 |
| Baseline cholesterol, mg/dL    | 0.143     | 1.007  | 0.998–1.015  |
| Baseline LDL, mg/dL            | 0.658     | 1.003  | 0.990–1.016  |
| Plasma NGAL, ng/mL             | 0.001     | 1.011  | 1.004–1.017  |

HR, hazard ratio; CI, confidence interval; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LDL, low density lipoprotein; NGAL, neutrophil gelatinase-associated lipocalin.
stitial fibrosis in renal biopsy (HR, 3.943; 95% CI, 1.132 to 13.731; \( p = 0.031 \)), documented proteinuria (> 1 g/day; HR, 7.128; 95% CI, 1.937 to 26.232; \( p = 0.003 \)), pNGAL (HR, 1.011; 95% CI, 1.004 to 1.017; \( p = 0.001 \)), and lower baseline eGFR (HR, 0.914; 95% CI, 0.869 to 0.961; \( p < 0.001 \)). Higher histological grade was not significantly associated with renal outcome (HR, 0.043; 95% CI, 0.000 to 722.358; \( p = 0.526 \)) (Table 3). In a multivariate analysis, HTN (HR, 8.779; 95% CI, 1.526 to 50.496; \( p = 0.015 \)), proteinuria > 1 g/day (HR, 5.184; 95% CI, 1.124 to 23.921; \( p = 0.035 \)), and pNGAL (HR, 1.012; 95% CI, 1.003 to 1.022; \( p = 0.013 \)) were independent predictors associated with the outcome of CKD stage 3 or above. However, after including serum creatinine in this model, the significance of NGAL was abolished (Table 4).

In the ROC curve analysis, pNGAL had a significant predictive value for adverse renal outcome (AUC = 0.777, \( p = 0.001 \)). pNGAL > 118.65 ng/mL predicted adverse renal outcome with 84.6% sensitivity and 68.7% specificity. ROC curve analysis showed considerable improvement of discriminative power for predicting adverse outcome with the addition of NGAL, compared with individual predictors, such as proteinuria and HTN. The AUC of this risk score reached 0.822 when all values were combined (Fig. 2).

**DISCUSSION**

In this study, we demonstrated that pNGAL in patients with IgAN was significantly higher in patients with adverse renal outcome and showed strong correlations with tubular atrophy/interstitial fibrosis and other clinical variables. As an independent predictor, pNGAL, when added to well-known predictive factors, including proteinuria and HTN, improved the predictive power for adverse outcomes. To our knowledge, this is the first reported study on the prognostic value and the correlation of pNGAL with other clinical variables in IgAN.

IgAN is a progressive disease with a highly variable clinical presentation and renal outcome [16]. No optimal treatment for IgAN has yet been established. General treatments, such as control of blood pressure with ACEi or ARBs, and statin therapy are generally administered to patients with IgAN to slow progression, while immunosuppressive therapy is used in selected patients.

---

**Table 4. Multivariate Cox regression analysis of factors affecting adverse renal outcomes**

| Characteristic | Model 1 \(^a\) | Model 2 \(^b\) | Model 3 \(^c\) | Model 4 \(^d\) |
|---------------|----------------|----------------|----------------|----------------|
| Plasma NGAL, ng/mL | 1.009 (1.002–1.017) | 1.012 (0.999–1.026) | 1.012 (0.999–1.026) | 1.011 (0.999–1.021) |
| Age | 1.018 (1.009–1.027) | 1.012 (1.003–1.022) | 1.012 (1.003–1.022) | 1.011 (1.000–1.021) |
| Hypertension | - | - | - | 8.779 (1.639–46.996) |
| Proteinuria (> 1 g/day) | - | - | - | 4.306 (0.786–23.996) |
| Serum creatinine, mg/dL | - | - | - | 76.942 (6.64–2,737.14) |

HR, hazard ratio; CI, confidence interval; NGAL, neutrophil gelatinase-associated lipocalin.

\(^a\)In the step-wise approach adopted here, predictors were entered sequentially.

\(^b\)Except for serum creatinine, hypertension, proteinuria > 1 g/day, and plasma NGAL were independent predictors of adverse renal outcome.

\(^c\)After including serum creatinine, the significance of NGAL was abolished.
Indications for immunosuppressive therapy are based on the perceived risk factors for progressive kidney disease. Such patients are more likely to benefit from early or more aggressive therapy [3,17]. Previous studies have identified clinical and pathological features associated with adverse renal outcomes. These include heavy proteinuria, reduced renal function, HTN at the time of diagnosis, interstitial fibrosis, and glomerular sclerosis [18,19]. However, the overall predictive value of these variables is relatively low. Thus, more accurate prognostic tools are needed to more accurately predict the course of IgAN.

In our study, because adverse renal outcome was defined as CKD stage 3 or above, initial serum creatinine was a strong prognostic factor. pNGAL also showed a positive association with initial creatinine ($r = 0.336, p = 0.001$). For these reasons, in multivariate analysis including serum creatinine, the variables did not show statistical significance. However, in multivariate analysis except serum creatinine, HTN, proteinuria > 1 g/day, and pNGAL were independent predictors of adverse renal outcome.

An increase in NGAL levels is a good predictor of the short-term onset of AKI, notably anticipating the resulting increase in serum creatinine levels. In parallel, recent studies have also reported altered NGAL levels in patients affected by CKD [10-12]. However, fewer studies on the association between NGAL and adverse renal outcome in IgAN have been reported. Ding et al. [20] reported that urinary NGAL was an early biomarker for renal tubulointerstitial injury in IgAN. Consistently, another study by Peters et al. [21] reported urinary kidney injury molecule-1 (KIM-1) and NGAL were independent predictors of ESRD in patients with IgAN. However, urinary KIM-1 and NGAL did not show correlations with renal function, and only KIM-1 was an independent predictor of ESRD. This is consistent with several recent reports showing correlations of NGAL with serum creatinine, eGFR, urinary PCR, and tubular atrophy [10-12,21]. In this study, pNGAL also showed strong correlations with age, creatinine, eGFR, uric acid, urinary PCR, and albumin.

Histological features identified as independent predictors of adverse renal outcome included glomerulosclerosis, tubular atrophy, interstitial fibrosis, and mesangial hypercellularity in IgAN [22-24]. In this study, pNGAL concentration showed a good correlation with tubular atrophy/interstitial fibrosis. Similarly, pNGAL has been shown to represent a biomarker for degree of tubulointerstitial damage in patients with CKD [14,15]. Thus, pNGAL concentration could be a valuable indicator for tubular atrophy/interstitial fibrosis in IgAN, especially in a situation where a renal biopsy could not be performed.

Using ROC curve analysis, pNGAL was found to be a strong prognostic factor for adverse renal outcome. As the predictive power of individual risk factors in IgAN is low, several clinical studies have suggested combining them to increase the predictive power versus individual risk factors [2,3,25]. In this study, the predictive power of pNGAL for adverse renal outcome showed considerable improvement when it was added to well-known clinical predictors, such as proteinuria and HTN. Thus, pNGAL could be used as a clinically relevant risk factor to increase predictive power for adverse outcomes in IgAN.

Although, the current study was somewhat limited by its retrospective design and also underpowered with small numbers of patients and short duration of follow-up period, our study is important because pNGAL
was significantly higher in patients with adverse renal outcomes and showed strong correlations with tubular atrophy/interstitial fibrosis and other clinical variables. The clinical applicability of these findings needs to be confirmed in a larger cohort. In this analysis, adjustment for initial serum creatinine could not be performed.

In summary, pNGAL may be useful as a potential predictor of prognosis for IgAN with other clinical parameters and also as a diagnostic indicator of tubular atrophy/interstitial fibrosis in IgAN. Further studies in larger populations are required to evaluate the potential utility of NGAL measurements in the monitoring of disease progression in IgAN.

**KEY MESSAGE**

1. In immunoglobulin A nephropathy (IgAN), plasma neutrophil gelatinase-associated lipocalin (pNGAL) showed strong correlations with other clinical prognostic factors.
2. pNGAL may be useful as a potential predictor of prognosis for IgAN with other clinical parameters and also as a diagnostic indicator of tubular atrophy/interstitial fibrosis.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This study was supported by a grant (A102065, A111345) from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affair, Republic of Korea.

**REFERENCES**

1. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988;12:340-347.
2. Berthoux FC, Mohey H, Afhani A. Natural history of primary IgA nephropathy. Semin Nephrol 2008;28:4-9.
3. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score.
4. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
5. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001;38:728-735.
6. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008;241:89-94.
7. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007;71:967-970.
8. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-621.
9. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;12:595-605.
10. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 2008;31:255-258.
11. Bhavsar NA, Kottgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2012;60:23-240.
12. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337-344.
13. Phillips AO. The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 2003;3:491-496.
14. Nickolas TL, Forster CS, Sise ME, et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int 2012;82:718-722.
15. Nielsen SE, Rossing K, Hess G, et al. The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scand J Clin Lab Invest 2012;72:137-142.
16. Kiryluk K, Julian BA, Wyatt RJ, et al. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol 2010;25:2257-2268.
17. Okazaki K, Suzuki Y, Kobayashi T, Kodama F, Horikoshi S, Tomino Y. Influence of the period between onset of IgA nephropathy and medical intervention on renal prognosis. Health 2011;3:518-523.
18. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese: clinical and pathological perspectives. Nephrol Dial Transplant 2002;17:64-69.
19. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24:179-196.
20. Ding H, He Y, Li K, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007;123:227-234.
21. Peters HP, Waanders F, Meijer E, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:3581-3588.
22. D’Amico G, Minetti L, Ponticelli C, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986;39:63-78.
23. Bogenschutz O, Bohle A, Batz C, et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 1990:10:137-147.
24. Katafuchi R, Oh Y, Hori K, et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol 1994;41:191-198.
25. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009;24:3668-3674.